Resultados de la búsqueda 801-810 of 5695 for litzow
Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...
Patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC) including fallopian tube and primary peritoneal cancer expressing high ...
Litzow, Mark R. M.D.. Minnesota. Patnaik, Mrinal S. M.B.B.S.. Minnesota. Pruthi, Rajiv K. K. M.B.B.S.. Minnesota. Escrito por el personal de Mayo Clinic.
El descubrimiento llega para los que están en la búsqueda. Tratamientos innovadores y de invasión mínima contra la enfermedad pulmonar. Dr. Sebastián Fernández- ...
The purpose of this study is to design, develop and assess the performance characteristics of NGS assays using circulating tumor DNA for the detection of ...
Rochester, Minn. The purpose of this study is to evaluate thymoma recurrence rates in patients who underwent thymectomy. 3D Ultrasound Imaging for Breast Cancer ...
This study is being conducted to see if adding Exemestane to the immune checkpoint blockade can slow disease progression in post-menopausal women with non-small ...
Rochester, Minn. Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies. A Study to Evaluate VSV-hIFNbeta-NIS to Treat ...
Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by ...
The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS) in addition to the Breast Cancer Risk Assessment ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?